A multi-institutional, prospective, observational study of a combination of atezolizumab and chemotherapy for patients with large cell neuroendocrine carcinoma (LCNEC) of the lung (NEJ044)
Not Applicable
Recruiting
- Conditions
- arge cell neuroendocrine carcinoma (LCNEC) of the lung
- Registration Number
- JPRN-UMIN000040876
- Lead Sponsor
- orth East Japan Study Group (NEJSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Subjects who could not give their consent. 2. Subjects with illnesses or conditions that interfere with their capacity to understand, follow and/or comply with study procedures.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year survival rate
- Secondary Outcome Measures
Name Time Method